Peter is Co-Chair of the firm's Patent Practice Group. Peter's practice is devoted to patent prosecution and patent licensing and litigation in the technology areas of pharmaceuticals, specialty chemicals, biotechnology, medical devices and other mechanical and electro-mechanical innovations particularly as relating to the automotive industry.
Peter's clients include academic and governmental research institutions; Global 1000 manufacturing, chemical and pharmaceutical companies; emerging and developing biotechnology and small molecule pharmaceutical companies; and medical device companies.
Peter prosecutes and manages extensive patent and trademark portfolios on behalf on companies and academic institutions located throughout the United States, Asia, and Europe.
Peter is named in The Best Lawyers in America publication. Peter has been included in the New England Super Lawyers listing, a Thomson Reuters publication, each year since 2004. He is rated AV Preeminent by Martindale-Hubbell and has been recognized as an IP Star by Managing Intellectual Property. Peter was named one of Boston's Top Rated Lawyers of 2014. Pete also has been named as a Life Science Star in the 2014 publication of LMG Life Sciences North America report.
Peter was hailed as a lawyer with a keen eye for detail and an understanding of what is commercially critical to his clients by Intellectual Asset Management in the 2014 edition of IAM Patent 1000 World's Leading Patent Practitioners.
Peter has been quoted on intellectual property topics in various publications, including The New York Times, Bloomberg, The Los Angeles Times, The Boston Globe, American Lawyer and Boston Business Journal.
•Peter has considerable experience in patent prosecution matters. Peter has prepared, prosecuted and managed extensive patent portfolios for global manufacturing companies. Peter also has drafted and prosecuted patent applications covering pharmaceutical, biotechnology and medical device products that are currently in Phase II and III trials as well as in approved clinical use in the United States and abroad. Peter has obtained patents that have yielded tens of millions of dollars in royalties as well as provided the basis for private and public financings of companies located throughout the United States, Asia, and Europe.
•Peter also represents parties in intellectual property disputes, including patent and trademark infringement actions. Peter has recently handled several Inter Partes Reviews. Peter has represented both opponents and patentees in numerous oppositions in Europe, Japan and Australia. Peter regularly provides opinions on issues of patent infringement and validity.
•Peter has served as the President of the Boston Patent Law Association (BPLA). Peter has also served as Co-Chair of the BPLA's Amicus Committee, Chair of the Chemical Patent Practice Committee and on the Board of Governors of the BPLA.
Before Edwards Wildman
Prior to attending law school, Peter was a synthetic organic chemist in a drug discovery group of E.I. DuPont de Nemours Co., Medical Products Department (later the DuPont Pharmaceutical Company and now merged with Bristol-Myers Squibb), in Wilmington, Delaware. Peter is an inventor on U.S. Patent 4,977,173 Aminomethyl Oxooxazolidinyl Ethenylbenzene Derivatives Useful As Antibacterial Agents, which covers predecessor development compounds to Pfizer's oxazolidinone antibacterial Zyvox, now in clinical use.
Besides Edwards Wildman
Peter has been active in a variety of youth sports programs, including coaching local soccer, wrestling, and baseball teams, and has served as the Director of the Wellesley Youth Wrestling Program. Peter also recently completed several triathlons and regularly golfs and skis with his sons and daughter.
Hot Topics in European and US Patent Law
April 1, 2014 event
Edwards Wildman Client Advisory - U.S. Patent and Trademark Office Issues Guidance in View of Prometheus and Myriad
Edwards Wildman Client Advisory: Supreme Court Invalidates Claims to Isolated DNA, but Upholds Patent Eligibility of cDNA in Myriad
Edwards Wildman Client Advisory - USPTO Publishes Final Rules and Examination Guidelines for Implementing First-Inventor-to-File Provisions of America Invents Act
February 14, 2013
Edwards Wildman: Direct Infringement by Single Entity Not Necessary for Induced Infringement of Method Patent
September 4, 2012
Obtaining an ITC Exclusion Order
May 22, 2012 event
Edwards Wildman Client Advisory - Biomedical Diagnostic Patents Post-Prometheus
March 21, 2012
Developing Nations: The Challenges of Technology Commercialization
March 12, 2012 event
The National Academy of Inventors
April 22, 2011 event
2nd Annual Drug Discovery Partnership: Filling the Pipeline
October 28 - 29, 2010 event
Edwards Wildman Honored for Excellence in the IAM Patent 1000 - The World's Leading Patent Practitioners 2014
June 6, 2014
Edwards Wildman Honored in Managing IP's IP Stars 2014
May 14, 2014
Edwards Wildman's Pete Corless Addresses Medical Devices in Emerging Markets in Intellectual Property Magazine
July 12, 2013
Edwards Wildman Recognized in Managing IP's 2013 World IP Handbook
June 18, 2013
Edwards Wildman's Pete Corless Analyzes Generic Drug Case in Life Sciences Intellectual Property Review
May 2, 2013
Edwards Wildman's Pete Corless and Ralph Loren Examine Bowman v Monsanto in Intellectual Property Magazine Article
April 18, 2013
Edwards Wildman's Pete Corless Comments on Google Fight against NPEs in World Intellectual Property Review
April 9, 2013
Edwards Wildman's Pete Corless Analyzes US Supreme Court Patent Case in Bloomberg
February 12, 2013
Edwards Wildman's Pete Corless Comments on Patent Suits Filed in Texas in World Intellectual Property Review
January 25, 2013
Pete Corless Breaks Down Federal Circuit Ruling on Induced Infringement in IP Law360
September 5, 2012